# The Forgotten Mothers: Anti\-D, Pooled Plasma and the Overlooked History of Risk

By The Unheard Voice

There is a group of women whose place in the history of contaminated blood products is rarely discussed. They were not necessarily receiving Factor VIII, and they were not necessarily transfusion patients. They were mothers.

Specifically, they were Rhesus-negative women who received Anti-D immunoglobulin during pregnancy or following childbirth.

Anti-D has prevented enormous suffering and protected babies from haemolytic disease. Its importance to maternity medicine is not in dispute. But Anti-D is also a human plasma-derived medicinal product, and its history raises questions that deserve careful examination.

Not because the evidence establishes a widespread British Anti-D contamination scandal. It does not. But because contaminated Anti-D unquestionably transmitted hepatitis C elsewhere, and the UK Infected Blood Inquiry recorded that some Irish-manufactured Anti-D was imported into Britain and administered to a small number of women.

That creates a much narrower, but very real, historical question: who were those women, what happened to them, and what records remain?

What is Anti-D?

Anti-D immunoglobulin is used to prevent Rhesus sensitisation.

When an RhD-negative woman carries an RhD-positive baby, exposure to the baby’s blood can sometimes cause her immune system to produce antibodies against RhD-positive red blood cells. Those antibodies can endanger a subsequent RhD-positive pregnancy.

Anti-D immunoglobulin significantly reduces that risk. It is manufactured from donated human plasma containing anti-D antibodies, which means its history belongs, at least partly, within the wider history of blood-product safety.

What happened with contaminated Anti-D?

The clearest documented Anti-D contamination scandal occurred in Ireland.

Anti-D manufactured by the Irish blood service transmitted hepatitis C to women who received the product. Research published after a national screening programme found evidence of past or current hepatitis C infection in hundreds of women who had received Anti-D.

A later transmission episode involving Irish Anti-D manufactured during the early 1990s was also documented. These events are established historical fact.

But Britain’s history was different.

Evidence considered by the UK Infected Blood Inquiry stated that intramuscular Anti-D manufactured in the UK had no established reports of viral transmission. The Inquiry also recorded, however, that Irish-manufactured Anti-D had been imported into the UK and administered on a named-patient basis to a small number of women.

The evidence therefore does not justify saying that British Anti-D caused a widespread hepatitis outbreak. But it does justify examining what happened to the women who received imported product.

What do we know about those UK recipients?

That is where the history becomes less clear.

The Inquiry heard evidence that imported Anti-D would normally have been used on a named-patient basis. That suggests records may once have existed identifying recipients.

Important questions therefore remain. How many women in Britain received Irish-manufactured Anti-D? At which hospitals? Which batches were involved? Were recipients subsequently identified, contacted or tested for hepatitis C? What documentation survives?

And if a woman or her family now approaches the compensation system but her maternity records no longer establish the manufacturer or batch, how is that history assessed?

These are questions, not accusations. They arise directly from the historical record.

Hepatitis B must be discussed accurately

Hepatitis B is also part of the infected blood scandal.

But the evidence we have reviewed does not justify presenting Anti-D as an established widespread source of hepatitis B infection among British mothers. Those two issues must not be conflated.

The current Infected Blood Compensation Scheme recognises chronic hepatitis B. Acute hepatitis B is treated more narrowly: current rules include cases where infection resulted in death from acute liver failure within 12 months of infection or reactivation.

Acute hepatitis C, by contrast, has a separate non-fatal eligibility category. That difference is real, and families are entitled to ask what medical and policy reasoning produced it.

But that debate should stand on its own evidence rather than being used to imply an Anti-D and hepatitis B connection that has not been established.

Missing records matter

One difficulty appears repeatedly across historic infected-blood cases: records from treatment decades ago may be incomplete, unavailable or incapable of identifying precisely which product was administered.

For Anti-D cases, that distinction can be crucial.

A woman may know she received Anti-D after childbirth, and her records may confirm she was RhD-negative. Yet the surviving documentation may no longer reveal the manufacturer or batch.

Where imported product was used only exceptionally, proving that exception decades later could become extremely difficult. That makes the evidential approach taken today important.

The question should not be whether every Anti-D recipient is presumed to have been exposed to contaminated product. The evidence does not support that.

The question is what happens where there is a plausible historical case but the surviving NHS record can no longer establish precisely which product was administered.

The women who cannot answer for themselves

Many women treated in the 1970s, 1980s and early 1990s have since died. Their families may now be trying to reconstruct maternity treatment from records created decades ago.

Those women cannot explain what they were told. They cannot remember packaging or batch numbers, and they cannot challenge assumptions about the source of an infection.

That is precisely why historical accuracy matters.

Families do not need exaggerated claims. They need records, surviving supply information and clear evidential standards.

And where imported Anti-D genuinely may have been administered, they need a fair process for establishing what happened.

Questions that remain

The historical record leaves several important questions.

How much Irish-manufactured Anti-D entered the UK, and during which years? Which hospitals or regional blood services received it? How many patients received it? Which batches were involved?

Were recipients subsequently traced or offered testing? What records of those processes survive today? And how are historic cases assessed where Anti-D treatment is documented but the manufacturer or batch can no longer be established?

These are not allegations. They are questions arising from the documented history of a plasma-derived treatment and from evidence considered by the Infected Blood Inquiry.

Why this history still matters

Anti-D has protected generations of mothers and babies. That should never be obscured.

But another part of its history should not be forgotten either.

Contaminated Anti-D caused a major hepatitis C tragedy in Ireland, and the UK Infected Blood Inquiry recorded that some Irish-manufactured product was administered to a small number of women in Britain.

That does not establish a widespread British Anti-D contamination scandal. It does establish that this history reached the UK.

For families trying to understand infections that occurred decades ago, surviving records, supply information and fair evidential standards still matter.

The responsible approach is not to exaggerate what is known. It is to preserve the history accurately, identify what remains unclear, and continue examining the evidence.

Because unanswered history should not become forgotten history.

— The Unheard Voice